Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA4Ag vaccine in spinal fusion surgery
NCT02388165Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jul 2015
- Primary completion
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in Staphylococcus aureus infection comparing SA4Ag with Placebo (2 arms). Primary endpoints: Number of Participants With Postoperative Staphylococcus (S.) Aureus Bloodstream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 90 Days…, Percentage of Participants With Local Reactions Within 10 Days After Vaccination and 4 more. Started Jul 2015; status: terminated.
02
Drugs
Staphylococcus aureus 4-antigen vaccine
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT02388165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388165.